SpecificationsOrganism/cell line/tissueHomo sapiens/mammary epithelial cells (HMEC)/mammary glandSexFemaleSequencer or array typePrimeView Human Gene Expression ArrayData formatRaw and normalizedExperimental factorsND (No Dox), 24 + (Dox treatment for 24 h), 72 + (Dox treatment for 72 h) and DW (Dox Withdrawn; Dox treatment for 24 h and Dox withdrawn for 48 h)Experimental featuresHMEC conditionally expressing (Doxycycline inducible) RelAConsentFreely availableSample source locationNA

1. Direct link to gene expression data deposited in Gene Expression Omnibus (GEO) {#s0005}
=================================================================================

<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65040>.

2. Materials, methods and experimental design {#s0010}
=============================================

2.1. Materials {#s0015}
--------------

Late passage P16^neg^ hTERT immortalized Human Mammary Epithelial Cells (HMEC) were a gift from Jean Zhao [@bb0030]. The cells were cultured in DMEM-F12 (Life Technologies) supplemented with Insulin (10 μg/ml; Life Technologies), Epidermal Growth Factor (10 ng/ml, Peprotech), Cholera Toxin (1 ng/ml, Sigma Aldrich), Hydrocortisone (500 ng/ml, Sigma-Aldrich) and 0.6% FBS (Clontech Laboratories). Phoenix cells (Orbigen) were cultured in DMEM supplemented with 10% FBS (Clontech). Other chemicals used in the study were: Anti-Anti (Life Technologies) Doxycycline (Sigma-Aldrich), Neomycin (Sigma Aldrich), Puromycin (Invivogen), and miRNeasy mini kit (Qiagen). The PrimeView Human Gene Expression Array from Affymetrix was used to estimate genome-wide gene expression levels.

2.2. Methods {#s0020}
------------

Retroviruses encoding the Tetracycline promoter transactivator (neomycin selection) and Flag-tagged RelA (Puromycin selection) were generated in Phoenix cells using standard protocols. HMEC were incubated with filtered culture supernatant containing virus particles and Polybrene (5 μg/ml, Millipore) for 12 h. Infected HMEC were selected using Neomycin (400 μg/ml) and Puromycin (1 μg/ml). Resulting cell line was designated HRA (HMEC harboring RelA) and pooled stable clones were used in the experiment. Dox inducible (1 μg/ml) expression of RelA and reduction of RelA expression after withdrawal of Dox were confirmed by Western blot [@bb0005].

HRA cells were plated in 6 well plates and 24 h later, treated with Dox according to the scheme in [Fig. 1](#f0005){ref-type="fig"} to generate triplicate samples for gene expression analysis. ND (No Dox; un-treated samples) were harvested 48, 72 and 96 h post-plating (indicated by red arrows in [Fig. 1](#f0005){ref-type="fig"}). To generate the 24 + samples, independent samples were treated with Dox 24, 48 and 72 h post-plating (indicated by green arrows) and harvested 24 h later (indicated by red arrows). The 72 + samples were treated with Dox 24 h post plating (green arrow) and harvested after 96 h of Dox treatment. The DW (Dox Withdrawn) sample was generated by treating cells with Dox 24 h post plating (green arrow), Dox withdrawn 24 h later (black arrow) and harvested after 48 h (red arrow). Culture medium in every plate was replaced with fresh medium containing Dox or devoid of Dox as required 24 h post-plating and every 24 h thereafter. For harvesting total RNA, the plates were transferred to ice, cells were washed with cold PBS and lysed using Trizol. Total RNA was purified using the miRNeasy mini kit from Qiagen using the manufacturer\'s protocol. The Affymetrix PrimeView array was used to estimate gene expression. RNA labeling, hybridization and scanning were performed at the Molecular Biology Core Facilities at Dana-Farber Cancer Institute according to manufacturer\'s protocol.

2.3. Gene expression analysis {#s0025}
-----------------------------

Quality checks of the expression data cel files were performed using AffylmGUI in R and data from all arrays was confirmed suitable for downstream analysis [@bb0035]. The cel files were normalized using RMA in GenePattern [@bb0040]. The Brainarray chip definition file (version 18) based on ensemble gene (ENSG) was used for probe summarization [@bb0045]. Differentially expressed genes between pairs of samples were identified using LIMMA implemented in MEV [@bb0050]. Other downstream analysis performed using the dataset is described in a previous manuscript [@bb0005].

3. Conclusion {#s0030}
=============

This dataset may be useful for identifying predictive biomarkers of response to CDK4/6 inhibitors e.g. Palbociclib, Abemaciclib, LEE011 and P1446A-05 in RB1 competent tumors where CDK4 is not amplified [@bb0055], [@bb0060], [@bb0065], [@bb0070].
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![Schematic representation of Dox treatment of HRA cells to regulate RelA expression. Open boxes indicate the absence of Dox, blue boxes indicate the presence of Dox. Green arrows indicate times at which Dox was added, black arrow indicates withdrawal of Dox and red arrows indicate time at which each sample was harvested for RNA extraction. The names of triplicate samples are given for each treatment condition.](gr1){#f0005}
